GIP receptor
GIP provides one glucose-dependent incretin signal at the pancreatic beta cell and contributes to the drug’s metabolic effects.
Back to Peptide Library
Dual Incretin Agonist
Tirzepatide
GIP / GLP-1 • Once-weekly SubQ injection
Tirzepatide activates GIP and GLP-1 receptors. Approved branded formulations are used for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea in eligible adults. Large trials show substantial weight loss and glucose improvement.
At a glance
Tirzepatide Quick Reference
- Starting dose
- Members onlySign in to view dosing details.
- Maintenance
- Members onlySign in to view dosing details.
- Maximum
- 15mg weeklyAfter gradual titration
- Route
- SubQ InjectionSame day each week
Overview
What Is Tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide that activates both GIP and GLP-1 receptors. A fatty-acid side chain supports albumin binding and a half-life of roughly five days, allowing once-weekly administration.
It is approved as Mounjaro for type 2 diabetes and as Zepbound for long-term weight management. Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Those approvals apply to the regulated branded formulations.
The dual mechanism separates tirzepatide from single-receptor GLP-1 medicines. GIP and GLP-1 signaling both affect glucose-dependent insulin release, while GLP-1 activity slows gastric emptying and contributes to appetite reduction.
Mechanism
Tirzepatide Mechanism of Action
GLP-1 receptor
GLP-1 adds satiety signaling, slows gastric emptying, and supports glucose-dependent insulin release.
Weekly exposure
Albumin binding extends exposure, enabling once-weekly administration rather than a short-lived pulse.
Combined response
Together, the two receptor pathways produced substantial weight reduction and glucose improvement in controlled trials.
Research findings
Tirzepatide Benefits
The findings below come from studied branded formulations and trial populations; individual results vary.
Substantial Weight Loss
SURMOUNT-1 reported 15.0%, 19.5%, and 20.9% average loss at 5mg, 10mg, and 15mg over 72 weeks.
Compared With Semaglutide
In SURMOUNT-5, maximum-tolerated tirzepatide produced 20.2% average weight loss versus 13.7% with semaglutide at 72 weeks.
Body Composition
A SURMOUNT-1 DEXA analysis attributed roughly three-quarters of weight lost to fat mass and one-quarter to lean mass.
Blood Sugar Control
SURPASS trials found substantial HbA1c reductions in people with type 2 diabetes, including a direct comparison with semaglutide 1mg.
Liver Research
In the phase 2 SYNERGY-NASH trial, MASH resolution without worsening fibrosis occurred more often with tirzepatide than placebo.
Sleep Apnea
SURMOUNT-OSA reported reductions in apnea-hypopnea events in adults with obesity and moderate-to-severe OSA.
Protocol planning
Tirzepatide Dosing Protocol
Members Access Only
Sign in or create a free account to view this content.
Preparation
Tirzepatide Reconstitution
Reconstitution Example
10mg RUO vial + 2mL bacteriostatic water
Result5mg/mL
Reconstitution steps
1
Prepare
Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.
2
Add diluent slowly
Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.
3
Dissolve gently
Swirl or roll the vial until the contents dissolve; do not shake.
4
Storage
Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.
N=1 reports
Tirzepatide Community Experience
Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.
Positive Reports
- Food noise and persistent thoughts about food often decrease substantially.
- Many users report meaningful weight loss, with pace varying by dose, baseline weight, nutrition, and adherence.
- Some people do well at lower doses without needing rapid escalation.
- Users who prioritize protein and resistance training describe better strength during weight loss.
Negative & Mixed Reports
- Nausea, constipation, diarrhea, fatigue, and sulfur burps are common during titration.
- Strong appetite suppression can make adequate calories, protein, and fluids difficult.
- Plateaus after several months do not automatically mean a dose increase is needed.
Stacking & synergy
Tirzepatide Stacking & Synergy
Tirzepatide already has strong evidence on its own. Pairing choices should address a specific goal without obscuring tolerability or increasing avoidable risks.
Resistance Training + Protein
The most practical pairing for preserving strength and lean mass during substantial weight loss.
Tirzepatide + CJC-1295 / Ipamorelin
Discussed for GH-axis and body-composition goals, but added muscle preservation has not been demonstrated in a controlled combination trial.
Other GLP-1 Products
Do not combine tirzepatide with another tirzepatide product or GLP-1 receptor agonist; FDA labeling does not recommend coadministration.
Insulin or Sulfonylureas
These combinations can increase hypoglycemia risk and may require clinician-supervised dose adjustment.
Safety notes
Tirzepatide Side Effects & Safety
Gastrointestinal effects are commonest during dose escalation. Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, jaundice, or allergic symptoms warrant medical evaluation.
Commonly Reported Effects
- Nausea, diarrhea, vomiting, constipation, decreased appetite, and abdominal discomfort.
- Reflux, belching, fatigue, dizziness, or injection-site reactions.
- Hair shedding can occur during substantial or rapid weight loss.
Important Risks
- Gallbladder disease, delayed gastric emptying, or possible pancreatitis.
- Vomiting or diarrhea can lead to dehydration-related kidney injury.
- Rapid weight loss without enough protein and resistance training can reduce lean mass and strength.
Tirzepatide Precautions
Do Not Use If You Have
- A personal or family history of medullary thyroid carcinoma.
- Multiple Endocrine Neoplasia syndrome type 2.
- Known serious hypersensitivity to tirzepatide or a product ingredient.
Use Caution With
- Pregnancy, or plans to become pregnant.
- Pancreatitis, gallstones, severe GI disease, or gastroparesis.
- Kidney disease or dehydration risk from GI symptoms.
- Diabetic retinopathy, rapidly improving glucose, or upcoming anesthesia.
- Insulin or sulfonylureas because of hypoglycemia risk.
Oral hormonal contraceptives may be less effective after starting tirzepatide or increasing the dose; FDA labeling advises a non-oral method or added barrier method for four weeks after each change. FDA approval applies to branded formulations, not automatically to RUO or compounded products.
Final verdict
Peptide Protocols Verdict on Tirzepatide
Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion
Tirzepatide sits just behind Retatrutide in our body-recomposition ranking. The dual GIP/GLP-1 action, large trials, and real-world track record make it one of the strongest options we discuss for appetite control and fat loss. In our community, people who keep up protein and resistance training tend to describe better strength and body composition than those who let appetite suppression drive intake too low.
We think Tirzepatide works best when the dose serves the goal rather than becoming the goal. We would hold an effective, tolerable dose and watch protein intake, strength, GI symptoms, and hydration instead of escalating automatically. Some researchers pair it with CJC-1295 / Ipamorelin, though the claimed extra muscle protection from that stack has not been proven. For mid-life recomp, it remains an elite tool when treated with respect.